ReviewJournal of cellular and molecular medicine2015
A proteomic approach to obesity and type 2 diabetes.
Review in Journal of cellular and molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exploring Biomarkers in Type 2 Diabetes Mellitus versus Normoglycemia Identified through High-Throughput Proteomics: A Systematic Review and Meta-Analysis.Journal of proteome research · 2026Pooled it
- Proteomic Insights into Childhood Obesity: A Systematic Review of Protein Biomarkers and Advances.International journal of molecular sciences · 2025Pooled it
- Protein quantitative trait locus study in obesity during weight-loss identifies a leptin regulator.Nature communications · 2017Trial
- Profound perturbations are found in the proteome and metabolome in children with obesity after weight loss intervention.Heliyon · 2024Article
- Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Comparison of Plasma Exosome Proteomes Between Obese and Non-Obese Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin.World journal of diabetes · 2022Article
- Plasma miR-193b-3p Is Elevated in Type 2 Diabetes and Could Impair Glucose Metabolism.Frontiers in endocrinology · 2022Article
- Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice.Journal of inflammation research · 2022Article
- Does Proteomic Mirror Reflect Clinical Characteristics of Obesity?Journal of personalized medicine · 2021Article
- Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease.Scientific data · 2020Article
- The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges.Current diabetes reports · 2019Review
- Precision medicine in adult and pediatric obesity: a clinical perspective.Therapeutic advances in endocrinology and metabolism · 2019Review
- Proteomic Analysis of Differentially-Expressed Proteins in the Liver of Streptozotocin-Induced Diabetic Rats Treated with Parkia biglobosa Protein Isolate.Molecules (Basel, Switzerland) · 2018Article
- Quantitative Proteomic Analysis of Hepatic Tissue of T2DM Rhesus Macaque.Journal of diabetes research · 2017Article
- Study of phosphorylation events for cancer diagnoses and treatment.Clinical and translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However, the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceutical communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.